Suppr超能文献

奥美拉唑和埃索美拉唑与低钠血症住院治疗的时间相关性。

Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia.

机构信息

Department of Clinical Science and Education at Södersjukhuset, Karolinska Institutet, Södersjukhuset, SE-11883, Stockholm, Stockholm, Sweden.

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

出版信息

Eur J Clin Pharmacol. 2023 Jan;79(1):71-77. doi: 10.1007/s00228-022-03423-x. Epub 2022 Nov 15.

Abstract

PURPOSE

The aim of this study was to explore the time-course of hospitalization due to hyponatremia associated with omeprazole and esomeprazole.

METHODS

In this register-based case-control study, we compared patients hospitalized with a main diagnosis of hyponatremia (n = 11,213) to matched controls (n = 44,801). We used multiple regression to investigate time-related associations between omeprazole and esomeprazole and hospitalization because of hyponatremia.

RESULTS

The overall adjusted OR (aOR) between proton pump inhibitor (PPI) exposure, regardless of treatment duration and hospitalization with a main diagnosis of hyponatremia, was 1.23 (95% confidence interval CI 1.15-1.32). Exposure to PPIs was associated with a prompt increase in risk of hospitalization for hyponatremia from the first week (aOR 6.87; 95% CI 4.83-9.86). The risk then gradually declined, reaching an aOR of 1.64 (0.96-2.75) the fifth week. The aOR of ongoing PPI treatment was 1.10 (1.03-1.18).

CONCLUSION

The present study shows a marked association between omeprazole and esomeprazole and hyponatremia related to recently initiated treatment. Consequently, newly initiated PPIs should be considered a potential culprit in any patient suffering from hyponatremia. However, if the patient has had this treatment for a longer time, the PPI should be considered a less likely cause.

摘要

目的

本研究旨在探讨与奥美拉唑和埃索美拉唑相关的低钠血症住院的时间进程。

方法

在这项基于登记的病例对照研究中,我们将因低钠血症住院的患者(n=11213)与匹配的对照(n=44801)进行比较。我们使用多元回归分析来研究奥美拉唑和埃索美拉唑与低钠血症住院之间的时间相关性。

结果

无论治疗持续时间和因低钠血症的主要诊断住院,质子泵抑制剂(PPI)暴露的总体调整比值比(aOR)为 1.23(95%置信区间 CI 1.15-1.32)。暴露于 PPIs 与低钠血症住院风险的迅速增加相关,从第一周开始(aOR 6.87;95% CI 4.83-9.86)。然后风险逐渐下降,第五周达到 aOR 1.64(0.96-2.75)。持续 PPI 治疗的 aOR 为 1.10(1.03-1.18)。

结论

本研究表明奥美拉唑和埃索美拉唑与与近期开始治疗相关的低钠血症之间存在显著关联。因此,新开始的 PPIs 应被视为任何患有低钠血症的患者的潜在罪魁祸首。然而,如果患者已经接受这种治疗更长时间,则应考虑 PPI 不太可能是原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b39/9816282/3b7034d1b102/228_2022_3423_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验